Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623915 | 0.78 | BACE1 (0.31) | BACE1BACE2OPRL1 | |
| SCHEMBL17169465 | 0.75 | BACE1 (0.46) | BACE1BACE2CYP2D6CTSD | |
| SCHEMBL16176015 | 0.72 | BACE1 (0.38) | BACE1BACE2CYP2D6 | |
| SCHEMBL30088411 | 0.72 | BACE1 (0.43) | BACE1BACE2CYP2D6 | |
| SCHEMBL30088354 | 0.72 | BACE1 (0.43) | BACE1BACE2CYP2D6 | |
| SCHEMBL16176020 | 0.72 | BACE1 (0.38) | BACE1BACE2CYP2D6 | |
| SCHEMBL17169248 | 0.71 | BACE1 (0.44) | BACE1BACE2CYP2D6CTSD | |
| SCHEMBL18636695 | 0.70 | BACE1 (0.40) | BACE1BACE2CYP2D6 | |
| SCHEMBL17118588 | 0.69 | BACE1 (0.40) | BACE1BACE2CYP2D6LMNAPOLB | |
| SCHEMBL18636692 | 0.69 | BACE1 (0.36) | BACE1BACE2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CYP2D6 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.